Advances in targeted drugs for follicular lymphoma

滤泡性淋巴瘤(follicular lymphoma,FL)是最常见的惰性淋巴瘤,在非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)中发病率仅次于弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL),具有易向DLBCL转化、缓解后复发率高等特点.美罗华的问世明显改善了滤泡淋巴瘤患者的预后,但并没有改变FL患者易复发的结局.随着针对FL的治疗新靶点包括Bcl-2、PI3K、PD-1等发现及其机制的进一步阐明,针对相应靶点的新药也开始进入临床试验,为改善FL患者的预后提供了新的可能.Follicular lymphoma(FL) is the most common indolent lymphoma,and the incidence in non-Hodgkin's lymphoma(NHL) was second only to diffuse large B-cell lymphoma(DLBCL).FL is easy to transform to DLBCL and relapse after remission.The advent of rituximab significantly improved the prognosis of patients with follicular lymphoma,but did not change the outcome of FL patients.With the discovery of new targets for FL,including Bcl-2,PI3K and PD-1,the new drugs targeting the target has begun to enter the clinical trial,which provides new possibilities to improve the quality of life for FL patients.203358-33602